Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion
Open Access
- 1 October 2024
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 8 (8) , e2400254
Abstract
Polyclonal convergent evolution to PARPi resistance in a patient with metastatic breast cancer with gPALB2.Keywords
This publication has 15 references indexed in Scilit:
- Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatmentNAR Cancer, 2022
- Targeting replication stress in cancer therapyNature Reviews Drug Discovery, 2022
- Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a reviewCancer and Metastasis Reviews, 2022
- Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case reportCancer Treatment and Research Communications, 2021
- A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistanceAnnals of Oncology, 2021
- Homologous recombination deficiency in breast cancer: Implications for risk, cancer development, and therapyGenes, Chromosomes and Cancer, 2020
- Olaparib for metastatic breast cancer in a patient with a germline PALB2 variantnpj Breast Cancer, 2020
- Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancerNature Communications, 2015
- Subclonal diversification of primary breast cancer revealed by multiregion sequencingNature Medicine, 2015
- Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancerAnnals of Oncology, 2014